BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 19010910)

  • 21. Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide.
    Guittet O; Tebbi A; Cottet MH; Vésin F; Lepoivre M
    Nitric Oxide; 2008 Sep; 19(2):84-94. PubMed ID: 18474260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.
    Lin HY; Kuo YC; Weng YI; Lai IL; Huang TH; Lin SP; Niu DM; Chen CS
    Prostate; 2012 Dec; 72(16):1767-78. PubMed ID: 22539223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
    Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
    J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
    Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
    Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
    Billam M; Sobolewski MD; Davidson NE
    Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.
    Tamura M; Yonezawa T; Liu X; Asada S; Hayashi Y; Fukuyama T; Tanaka Y; Kitamura T; Goyama S
    Sci Rep; 2019 Jun; 9(1):8171. PubMed ID: 31160638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A ribonucleotide reductase gene is a transcriptional target of p53 and p73.
    Nakano K; Bálint E; Ashcroft M; Vousden KH
    Oncogene; 2000 Aug; 19(37):4283-9. PubMed ID: 10980602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
    Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
    Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methyltransferases as targets for cancer therapy.
    Ghoshal K; Bai S
    Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
    Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
    Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
    Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
    Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
    Jacobberger JW; Woost PG
    Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
    Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
    Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.
    Ghoshal K; Datta J; Majumder S; Bai S; Kutay H; Motiwala T; Jacob ST
    Mol Cell Biol; 2005 Jun; 25(11):4727-41. PubMed ID: 15899874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.